BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 194 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $286,000 | -36.0% | 27,000 | -1.8% | 0.02% | -21.7% |
| Q1 2022 | $447,000 | +16.1% | 27,500 | -1.2% | 0.02% | +9.5% |
| Q4 2021 | $385,000 | -5.4% | 27,824 | -1.8% | 0.02% | -8.7% |
| Q3 2021 | $407,000 | -9.2% | 28,324 | 0.0% | 0.02% | -14.8% |
| Q2 2021 | $448,000 | +52.9% | 28,324 | -1.7% | 0.03% | +92.9% |
| Q1 2021 | $293,000 | +5.8% | 28,824 | -22.5% | 0.01% | 0.0% |
| Q4 2020 | $277,000 | +307.4% | 37,200 | +88.8% | 0.01% | +133.3% |
| Q3 2020 | $68,000 | +240.0% | 19,700 | +369.0% | 0.01% | +200.0% |
| Q2 2020 | $20,000 | – | 4,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |